Want to join the conversation?
Mark Altschwager of Robert W. Baird asks about SG&A guidance for 2H16. CFO Wes McDonald said it will depend on $KSS' results and the company will have more SG&A in 4Q16. He added that there will not be any great variability between 3Q16 and 4Q16.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.